Rigel Pharmaceuticals finalized its exclusive global license agreement with Arvinas and Pfizer for VEPPANU, a drug approved by the FDA to treat certain advanced breast cancers. The agreement became effective June 11, 2026, with Rigel paying $70 million upfront. VEPPANU targets ER+/HER2- breast cancer with ESR1 mutations after endocrine therapy failure. Rigel expects to launch VEPPANU commercially in August, expanding treatment options for this patient group.
Novo Nordisk reported a 4% sales decline in Q1 FY26 excluding a $4.2B accounting reversal, with key drugs Ozempic and Rybelsus dropping significantly. The company also announced major price cuts for Wegovy and Ozempic in 2027 and faced setbacks with ...
Eli Lilly reported a 55.5% revenue increase to $19.80B in Q1 2026, driven by obesity drugs Mounjaro and Zepbound, while Pfizer's revenue rose 5.4% to $14.45B, supported by Eliquis and oncology products but weighed down by declining COVID-related sale...
